Shareholders meeting

21ST ANNUAL REPORT BETA DRUGS LIMITED NOTICE TO SHAREHOLDERS NOTICE is hereby given that 21st Annual General Meeting of the Company will be held on Wednesday, 30th day of September, 2026 at 10.30 a.m. at registered office of the company situated at Village Nandpur, Lodhimajra Road, Baddi Distt Solan, H.P - 174101 to transact the following businesses: Ordinary Business: 1. Adoption of Financial Statements “To receive, consider and adopt the Audited Standalone Financial Statements and Audited Consolidated Financial Statements of the Company for the year ended March 31, 2026 including the Audited Balance Sheet as at March 31, 2026, and the Statement of Profit & Loss and Cash Flow Statement for the year ended on that date and the Reports of the Board of Directors and Auditors thereon.” 2. To appoint a director in place of Mr. Ajay Mahipal (DIN: 06949940), who retires by rotation and being eligible for, offers himself for re- appointment. 3. To appoint a director in place of Mr. Ashutosh Shukla (DIN: 09461568), who retires by rotation and being eligible, offers himself for re- appointment. 4. To re-appoint the Statutory Auditors of the Company from the conclusion of this Annual General Meeting until the conclusion of Twenty Third Annual General Meeting and to fix their remuneration: To consider and if thought fit to pass with or without modification the following resolution as Ordinary Resolution: ”RESOLVED THAT pursuant to Sections 139, 141,142 of the Companies Act, 2013 (“Act”) and other applicable provisions, if any, of the said Act and Companies (Audit and Auditors) Rules, 2014 made thereunder and other applicable rules, if any, under the said Act (including any statutory modification(s) or re-enactment thereof for the time being in force) and pursuant to the recommendation of the Audit Committee and the Board of Directors M/s Khurana Sharma & Co., (FRN- 010920N), Chartered Accountant be and is hereby re-appointed as the Statutory Auditors of the Company commencing from the conclusion of this Annual General Meeting till the conclusion of Twenty Third Annual General Meeting at a remuneration of Rs 4,20,000 p.a. in addition to the re-imbursement of applicable taxes and actual out of pocket and travelling expenses etc. incurred in connection with the audit as recommended by the Audit Committee and/or Board of Directors of the Company further subject to the approval of shareholders of the company.” “RESOLVED FURTHER THAT Mr. Rahul Batra, (DIN:02229234) Chairman cum Managing Director and/or Mr. Varun Batra, (DIN: 02148383) Joint Managing Director of the Company be and are hereby severally authorized to file necessary forms/returns with Registrar of Companies and to take such actions as may be necessary in this regard." Special Business: 5. To ratify the remuneration payable to the Cost Auditor appointed by the Board of Directors of the Company for the financial year 2026- 27 pursuant to Section 148 and all other applicable provisions of Companies Act, 2013. To consider and if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 148(3) of the Companies Act, 2013 read with Rule 14 of Companies (Audit and Auditors) Rules, 2014 and other applicable provisions of the Companies Act, 2013, the remuneration of Rs.1,25,000/-(Rupees One Lac twenty five thousand Only)with reimbursement of conveyance expenses at actual and GST as applicable payable to M/s Charu Jindal & Co, Cost Accountants, bearing Firm Registration Number 103508, for conducting cost audit of the Company for the financial year 2026-27, as approved by the Board of Directors of the Company, be and is hereby ratified.” “RESOLVED FURTHER THAT Mr. Rahul Batra, (DIN:02229234) Chairman cum Managing Director and/or Mr. Varun Batra, (DIN: 02148383) Joint Managing Director of the Company be and are hereby severally authorized to do all such acts, deeds, matters and things as it may in its absolute discretion consider necessary, proper or desirable for the purpose of giving effect to this resolution.” 6. Re-appointment of Mr. Ashutosh Shukla (DIN No. 09461568), as Whole time Director of the company w.e.f 20th January 2027 till 19th January 2032 and to revise the remuneration payable to Mr. Ashutosh Shukla. To consider and if thought fit to pass with or without modification the following resolution as Special Resolution:- 21ST ANNUAL REPORT BETA DRUGS LIMITED “RESOLVED THAT pursuant to recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors and pursuant to the provisions of sections 196, 197, 198, 203 and all other applicable provisions, if any, read with the schedule V of the Companies Act, 2013 and pursuant to the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended from time to time and other applicable provisions of the Companies Act, 2013 and Rules made thereunder (including any statutory modification(s) or re- enactment thereof for the time being in force and any subsequent amendment / modification in the Rules, Act and/or applicable laws in this regard, the approval of the Members of the Company be and is hereby accorded for the re-appointment of Mr. Ashutosh Shukla (DIN: 09461568), as Whole-time director of the company with effect from 20th January, 2027 upto period of ended 19th January 2032 on the terms and conditions including remuneration as mentioned below:- a) Remuneration: Rs 3,94,419 per month plus Diwali Bonus b) Incentive shall be paid additionally not exceeding the gross salary c) Perquisites: The Following perquisite shall not be included in the computation of the ceiling on remuneration: i) Contribution to provident fund, superannuation fund or annuity fund to the extent these either single or put together are not taxable under Income Tax Act, 1961. ii) Gratuity payable at the rate not exceeding half a month salary for each completed year of service. iii) Encashment of leave at the end of tenure. “RESOLVED FURTHER THAT Mr. Ashutosh Shukla (DIN:09461568) will also be entitled for the reimbursement of actual entertainment, travelling, boarding and lodging expenses incurred by her in connection with the company’s business and such other benefits and other privileges, as any from time to time be available to other senior executives of the company.” “RESOLVED FURTHER THAT subject to approval of shareholders, Board of the Directors are authorized to revised the remuneration (basic salary, allowances, perquisities, etc) from time to time by giving suitable increment / decrement after review of his performance each year, subject to the condition that total monthly remuneration not to exceed Rs. 10 lacs in any case.” “RESOLVED FURTHER THAT In case of absence or inadequacy of profits in any financial year, remuneration as mentioned above shall be paid to Mr. Ashutosh Shukla Chopra which may exceed the limits prescribed under Schedule V of Companies Act, 2013.” Dated: 03.09.2026 By Order of the Board of Directors Place: Panchkula sd/- Rahul Batra Chairman & Managing Director (DIN:02229234) 21ST ANNUAL REPORT BETA DRUGS LIMITED NOTES: 1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON POLL INSTEAD OF HIMSELF AND PROXY NEED NOT BE A MEMBER. PROXIES, IN ORDER TO BE EFFECTIVE, MUST BE RECEIVED BY THE COMPANY NOT LESS THAT 48 HOURS BEFORE THE COMMENCEMENT OF MEETING. 2. A PERSON CAN ACT AS PROXY ON BEHALF OF MEMBERS NOT EXCEEDING FIFTY AND HOLDING IN THE AGGREGATE NOT MORE THAN TEN PERCENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS. A MEMBER HOLDING MORE THAN TEN PERCENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS MAY APPOINT A SINGLE PERSON AS PROXY AND SUCH PERSON SHALL NOT ACT AS PROXY FOR ANY OTHER PERSON OR SHAREHOLDER. 3. Pursuant to the provisions of SEBI (LODR) Regulations, 2015 and section 91 of the Companies Act, 2013, Register of Members and Sha [Showing first 8,000 characters — download PDF for full document]